

IMMUNOGEN INC  
Form 8-K  
November 21, 2002

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Report) : November 19, 2002**

**ImmunoGen, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Massachusetts**  
(State or Other Jurisdiction  
of Incorporation)

**0-17999**  
(Commission  
File Number)  
128 Sidney Street  
Cambridge, MA 02139

**04-2726691**  
(I.R.S. Employer  
Identification No.)

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (617) 995-2500

**ITEM 5. OTHER EVENTS**

On November 19, 2002, Millennium Pharmaceuticals, Inc. informed ImmunoGen that clinical trials of the novel anti-cancer agent composed of ImmunoGen's DM1 effector molecule and Millennium's MLN591 antibody had been initiated. The achievement of this milestone triggers a milestone payment of \$1.0 million from Millennium to ImmunoGen. The press release announcing the achievement of this milestone is incorporated herein by reference and filed as Exhibit 99.1 hereto.

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS**

(c) Exhibits.

99.1 The Registrant's Press Release dated November 21, 2002.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

**ImmunoGen, Inc.**

Date: November 21, 2002

By:

/s/ Gregg D. Beloff

Gregg D. Beloff

Chief Financial Officer and Vice President